Logo image of MGX

METAGENOMI INC (MGX) Stock Fundamental Analysis

NASDAQ:MGX - Nasdaq - US59102M1045 - Common Stock - Currency: USD

2.36  -0.08 (-3.28%)

After market: 2.36 0 (0%)

Fundamental Rating

3

Overall MGX gets a fundamental rating of 3 out of 10. We evaluated MGX against 572 industry peers in the Biotechnology industry. While MGX has a great health rating, there are worries on its profitability. MGX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

MGX had negative earnings in the past year.
In the past year MGX has reported a negative cash flow from operations.
MGX Yearly Net Income VS EBIT VS OCF VS FCFMGX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 0 20M -20M -40M -60M -80M -100M

1.2 Ratios

MGX has a better Return On Assets (-20.64%) than 77.44% of its industry peers.
MGX has a better Return On Equity (-28.91%) than 79.57% of its industry peers.
Industry RankSector Rank
ROA -20.64%
ROE -28.91%
ROIC N/A
ROA(3y)-14.78%
ROA(5y)N/A
ROE(3y)-32.18%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MGX Yearly ROA, ROE, ROICMGX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 -10 -20 -30 -40

1.3 Margins

MGX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MGX Yearly Profit, Operating, Gross MarginsMGX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 -2K -4K -6K -8K

More info and screens

7

2. Health

2.1 Basic Checks

MGX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MGX remains at a similar level compared to 1 year ago.
There is no outstanding debt for MGX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
MGX Yearly Shares OutstandingMGX Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 10M 20M 30M
MGX Yearly Total Debt VS Total AssetsMGX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 100M 200M 300M 400M

2.2 Solvency

Based on the Altman-Z score of -0.11, we must say that MGX is in the distress zone and has some risk of bankruptcy.
MGX has a better Altman-Z score (-0.11) than 62.70% of its industry peers.
There is no outstanding debt for MGX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.11
ROIC/WACCN/A
WACC9.44%
MGX Yearly LT Debt VS Equity VS FCFMGX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 6.18 indicates that MGX has no problem at all paying its short term obligations.
MGX has a better Current ratio (6.18) than 62.34% of its industry peers.
A Quick Ratio of 6.18 indicates that MGX has no problem at all paying its short term obligations.
The Quick ratio of MGX (6.18) is better than 62.70% of its industry peers.
Industry RankSector Rank
Current Ratio 6.18
Quick Ratio 6.18
MGX Yearly Current Assets VS Current LiabilitesMGX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 100M 200M 300M

More info and screens

2

3. Growth

3.1 Past

MGX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -56.79%.
The Revenue has grown by 160.21% in the past year. This is a very strong growth!
EPS 1Y (TTM)-56.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3.32%
Revenue 1Y (TTM)160.21%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-6.87%

3.2 Future

The Earnings Per Share is expected to grow by 17.82% on average over the next years. This is quite good.
MGX is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -1.85% yearly.
EPS Next Y54.26%
EPS Next 2Y22.83%
EPS Next 3Y17.82%
EPS Next 5YN/A
Revenue Next Year21.73%
Revenue Next 2Y-10.47%
Revenue Next 3Y-1.85%
Revenue Next 5YN/A

3.3 Evolution

MGX Yearly Revenue VS EstimatesMGX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 10M 20M 30M 40M 50M
MGX Yearly EPS VS EstimatesMGX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 -1 -2 -3 -4 -5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

MGX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year MGX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MGX Price Earnings VS Forward Price EarningsMGX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MGX Per share dataMGX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

A more expensive valuation may be justified as MGX's earnings are expected to grow with 17.82% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.83%
EPS Next 3Y17.82%

More info and screens

0

5. Dividend

5.1 Amount

MGX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

METAGENOMI INC

NASDAQ:MGX (2/21/2025, 8:00:01 PM)

After market: 2.36 0 (0%)

2.36

-0.08 (-3.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2024-11-13/amc
Earnings (Next)N/A N/A
Inst Owners28.67%
Inst Owner Change-0.99%
Ins Owners12.92%
Ins Owner Change-0.08%
Market Cap88.31M
Analysts80
Price Target18.77 (695.34%)
Short Float %9.89%
Short Ratio0.93
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)45.46%
Min EPS beat(2)34.9%
Max EPS beat(2)56.01%
EPS beat(4)3
Avg EPS beat(4)28.57%
Min EPS beat(4)-51.7%
Max EPS beat(4)75.08%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)54.84%
Min Revenue beat(2)41.7%
Max Revenue beat(2)67.99%
Revenue beat(4)4
Avg Revenue beat(4)44.62%
Min Revenue beat(4)29.22%
Max Revenue beat(4)67.99%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)8.24%
EPS NQ rev (1m)-10.87%
EPS NQ rev (3m)9.78%
EPS NY rev (1m)0%
EPS NY rev (3m)16.15%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)10.34%
Revenue NY rev (1m)0%
Revenue NY rev (3m)16.45%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.6
P/FCF N/A
P/OCF N/A
P/B 0.35
P/tB 0.35
EV/EBITDA N/A
EPS(TTM)-2.5
EYN/A
EPS(NY)-2.69
Fwd EYN/A
FCF(TTM)-2.88
FCFYN/A
OCF(TTM)-2.76
OCFYN/A
SpS1.47
BVpS6.84
TBVpS6.84
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -20.64%
ROE -28.91%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-14.78%
ROA(5y)N/A
ROE(3y)-32.18%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.15
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 87.76%
Cap/Sales 8.2%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.18
Quick Ratio 6.18
Altman-Z -0.11
F-Score4
WACC9.44%
ROIC/WACCN/A
Cap/Depr(3y)596.64%
Cap/Depr(5y)N/A
Cap/Sales(3y)432.61%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-56.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3.32%
EPS Next Y54.26%
EPS Next 2Y22.83%
EPS Next 3Y17.82%
EPS Next 5YN/A
Revenue 1Y (TTM)160.21%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-6.87%
Revenue Next Year21.73%
Revenue Next 2Y-10.47%
Revenue Next 3Y-1.85%
Revenue Next 5YN/A
EBIT growth 1Y-75.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-18.21%
EBIT Next 3Y-31.91%
EBIT Next 5YN/A
FCF growth 1Y-742.81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-407.53%
OCF growth 3YN/A
OCF growth 5YN/A